What Alista Treats: Main Uses and Benefits

Alista is indicated for the management of symptoms associated with several distinct conditions. Its primary therapeutic domains involve the urinary system and blood circulation. The medication may assist in the relief of signs and symptoms related to benign prostatic hyperplasia (BPH), which commonly includes difficulty with urination, urinary urgency, and a weakened stream. Alista is also used to help in the management of pulmonary arterial hypertension (PAH) and to address symptoms of erectile dysfunction (ED). By helping to ease these issues, Alista aims to support patient comfort and quality of life within the context of these conditions.

Quick Fact: Relief for lower urinary tract symptoms associated with BPH

Who Can and Cannot Use Alista?

Eligibility for Alista (Cilostazol) is strictly defined by regulatory authorities and is based on critical cardiovascular health and organ function to ensure patient safety.

---

Contraindications (Who Must Not Use Alista)

Contraindicated Status	Examples of Prohibited Populations
Cardiovascular Risk	Patients with Heart Failure of any severity, or those with recent (within 6 months) Myocardial Infarction, Stroke, or TIA
Bleeding Risk	Patients with a known predisposition to bleeding (e.g., active pathological bleeding)
Organ Function	Patients with Severe Renal Impairment (creatinine clearance le 25 mL/min) or Moderate to Severe Hepatic Impairment

---

Age and Physiological Restrictions

• Pediatric Use: Safety and effectiveness have not been established in children (under 18 years of age), and use is generally not recommended in this population.
• Pregnancy and Breastfeeding: Use is contraindicated or not recommended during both pregnancy and lactation due to potential risks.
• Conditional Use: The use of Alista is restricted when combined with two or more additional antiplatelet or anticoagulant agents and requires special consideration and/or dose adjustment when taken with specific inhibitors of CYP3A4 or CYP2C19 enzymes.

Alista Interactions with other medicines and products

Official regulatory information requires careful attention to specific drug and substance combinations due to documented interaction potential. This section summarizes these official constraints.

Interaction Classification	Interacting Agents / Categories	Constraint / Action Required
Do Not Use Together	Tamoxifen	Combination should be avoided as it reduces Alista's plasma concentration (by approximately 27%) and does not offer additional efficacy benefit.
Do Not Use Together	Estrogen-containing therapies	This includes estrogen-containing medicines for hormone replacement or symptom relief. These agents may diminish the pharmacologic action of Alista (Anastrozole).
Use With Caution	Warfarin and other Anticoagulants	While clinical studies have indicated that Alista does not cause a clinically significant alteration to the pharmacokinetics or anticoagulant activity of Warfarin, monitoring for changes in anticoagulant effects (e.g., INR) and bleeding risk is still advised when co-administered.

Non-Medicinal Interactions:

Regulatory documents advise caution when Alista is co-administered with alcohol due to the potential for excessive sleepiness and increased risk of liver damage. Additionally, patients should not take herbal remedies or supplements for menopause symptoms, as these may contain estrogen-like compounds that can interfere with Alista’s therapeutic effects. The interaction profile is defined primarily by the need to strictly avoid co-administration with other anti-estrogen agents or estrogen sources.

Enzyme-Mediated Signaling Inhibition

Alista functions as a selective non-steroidal aromatase inhibitor. The compound targets and binds to the aromatase enzyme (CYP19A1), an enzyme critical for the conversion of androgens into estrogens, primarily in peripheral tissues. This binding interaction results in the suppression of enzyme activity and a block in the final step of estrogen synthesis.

Modulation of Hormone Synthesis Pathways

Inhibition of aromatase modifies this early molecular step, thereby altering downstream hormonal signaling pathways associated with steroidogenesis. By preventing the production of active estrogen, Alista initiates a signaling sequence that restricts the availability of this key mediator. This mechanism influences the hormonal feedback loops regulated by circulating estrogen levels.

System-Level Physiological Consequence

The engagement of this mechanism results in a decrease in plasma estrogen concentration. This reduction is a direct physiological consequence of the compound's modulation of the enzyme-mediated synthesis pathway, resulting in an altered state of hormonal signaling.

Alista is administered as an oral tablet and its use involves specific administration rules concerning timing, dosage, and patient factors.

Dosing Schedule and Timing

The standard dosing regimen is 100 mg taken twice daily (b.i.d.). A key instruction regarding administration is the requirement to take the medicine on an empty stomach. This means the tablet must be taken either 30 minutes before or 2 hours after both breakfast and the evening meal. This specific timing is required to manage the absorption of the drug.

---

Mandatory Dose Adjustments and Duration

The 100 mg twice daily dose is the standard regimen, but a dose reduction to 50 mg twice daily is utilized when Alista is co-administered with drugs known to inhibit the CYP3A4 or CYP2C19 enzymes. This modification is a procedural step to maintain appropriate drug exposure. Regarding duration, patients may need up to 12 weeks to experience a beneficial effect. If symptom improvement is unobserved after 3 months of therapy, the protocol indicates that the treatment should be discontinued.

---

Use Restrictions in Specific Populations

Dosing rules for Alista include explicit restrictions based on organ function. Use is not indicated for patients presenting with moderate or severe hepatic impairment. Similarly, the medicine is not indicated for patients with severe renal impairment, defined as having a creatinine clearance of ≤ 25 ml/min. Older adults, conversely, do not require any special dosage adjustments. Safety and effectiveness have not been established for administration in the pediatric population.

Research Evidence / Overview of Studies for Alista

---

Evidence for use in Psoriasis

Alista was studied for its use in individuals with Psoriasis, a condition characterized by inflammatory or irritative states of the skin. Research explored how Alista was observed in clinical trials designed to assess outcomes related to physical discomfort and the appearance of the skin lesions. These studies involved populations with Psoriasis who presented with cycles of stability and flare-ups.

The research examined changes measured during the study period. Findings described patterns observed in the studies related to how the skin symptoms evolved in the observed populations. While the research provides insight into short-term changes, evidence is limited regarding outcomes measured after the main study period. Furthermore, results apply only to the populations studied, and there may be variations in how individuals respond.

---

Evidence for use in Psoriatic Arthritis

Alista was also evaluated in studies focusing on Psoriatic Arthritis, a condition marked by functional limitations and inflammation in the joints and surrounding tissues. Studies focused on outcomes related to physical discomfort such as joint swelling and tenderness. Research describes patterns related to how joint symptoms evolved during defined time intervals.

It is important to note that while the evidence contributes to the broader evidence landscape, follow-up durations were limited in many key studies. Comparative evidence, which involves direct comparisons, is lacking in some areas, and the extent of available evidence varies.

---

Long-term Studies and Follow-up

Research concerning the long-term use of Alista was studied for how the initial findings may be maintained over time. This section outlines what is known about how findings may evolve—meaning whether the patterns observed initially were maintained during ongoing use.

Studies monitor how symptoms evolved in the observed populations over extended periods, but long-term effects are not fully established. Data for patterns observed over the long term and long-term consequences are still emerging. There is limited information for long-term outcomes beyond the duration of the main clinical trials.

---

What is still uncertain about Alista

This section clarifies the areas where knowledge about Alista is incomplete. Research highlights what is known—and what is still uncertain—about the treatment. Specifically, comparative evidence is lacking for many direct comparisons, and evidence quality varies across studies, leading to different findings in some research papers. This ongoing uncertainty indicates that research is ongoing to fill these knowledge gaps.

Key Studies & References

1. Joint AAD-NPF Guidelines of Care for the Management and Treatment of Psoriatic Disease

Common questions about Alista (FAQ)

Q: Does Alista need to be taken long-term?

A: According to official product information, treatment should be evaluated by a healthcare provider. If beneficial effects are unobserved after 3 months of therapy, official regulatory protocol stipulates that the treatment should be discontinued. The decision for continued use beyond this initial assessment period is a clinical one, determined by the healthcare provider.

Q: Does Alista affect sleep?

A: Studies and official information indicate that Alista may affect sleep. Insomnia (difficulty sleeping) is listed in regulatory documents as an uncommon or rare side effect that has been observed in patients.

Q: Can Alista be taken with blood pressure medication?

A: Regulatory documents advise that Alista should be used with caution when taken with other medicines intended to lower blood pressure. Alista itself may induce Hypotension (low blood pressure). Because of this potential for additive effects, monitoring by a healthcare provider may be necessary.

Q: Are there any foods or drinks to avoid while taking Alista?

A: Regulatory documents describe specific timing for Alista administration, stating it is required to be taken on an empty stomach. Additionally, official labeling advises caution when using alcohol due to the potential for excessive sleepiness and increased risk of liver damage. Grapefruit products should also be avoided.

Q: Is it safe to drink alcohol in small amounts while on Alista?

A: Official regulatory documents advise caution when taking Alista with alcohol due to the potential for excessive sleepiness and increased risk of liver damage. The advice to use caution applies generally to alcohol consumption due to the risks described in the official documents.

Q: Does Alista require any special monitoring or lab tests?

A: Monitoring for changes in anticoagulant effects (such as INR) is advised when Alista is co-administered with Warfarin. Due to the potential for rare, serious blood disorders (e.g., Agranulocytosis), regulatory documents advise that periodic monitoring of platelets and white blood cell counts may be necessary.

Q: Is Alista known to interact with herbal supplements like St. John's Wort?

A: Official regulatory information advises caution or avoidance of certain herbal remedies or supplements. The advisory includes supplements containing estrogen-like compounds, or those that are strong inhibitors or inducers of certain enzymes, such as St. John's Wort, which is noted for its enzyme interaction potential.

Q: Are there different strengths or forms of Alista available?

A: Alista is formulated and supplied as an oral tablet. Official drug information states that it is available in several strengths, including 50 mg and 100 mg.

Q: Is Alista known by any other name?

A: The drug is known by the trade name Alista. Its active ingredient is Cilostazol, which is also available under other brand names.

Q: What does the term 'contraindications' mean for Alista?

A: A contraindication is a regulatory term that lists specific patient conditions where the medicine must not be used. For Alista, this includes conditions like any degree of heart failure, severe organ impairment, or a known predisposition to bleeding.

Q: Does Alista cause any psychological side effects?

A: Official safety documents list a number of adverse reactions that affect the central nervous system. These include Insomnia (difficulty sleeping) and Dizziness.

Q: Is Alista available in liquid form?

A: According to official product information, Alista is formulated and supplied only as an oral tablet and is not typically available in a liquid form.

Q: What is the purpose of the 'Warnings and Precautions' section for Alista?

A: This regulatory section highlights serious, clinically significant risks or adverse reactions. This section alerts about conditions, such as Heart Failure or Hemorrhage events, that require a healthcare professional to perform a careful assessment of risk-benefit and may necessitate special patient monitoring.

Q: How is the safety of Alista monitored after it is approved?

A: Drug safety is continuously monitored after approval through a system called post-marketing surveillance. This regulatory process tracks the medicine's use to identify and study any rare or unexpected adverse reactions that were not observed in earlier clinical trials.

Q: Is Alista a type of antibiotic?

A: No, Alista is not classified as an antibiotic. The active ingredient, Cilostazol, is officially categorized as a Phosphodiesterase III (PDE3) inhibitor. This pharmacological class is associated with blood vessel dilation and the suppression of platelet activity.

Q: Does Alista have a Black Box Warning?

A: Yes, Alista carries a Boxed Warning in its official labeling from the FDA. This warning advises against its use in patients with heart failure of any severity due to official data indicating a potential risk.

Q: What happens if a person forgets to take a dose of Alista?

A: Official dosing instructions address how to proceed if a dose is forgotten, typically advising against doubling up on doses. The specific steps for a missed dose are detailed in the Patient Information Leaflet and should be reviewed with the prescriber.

Q: What happens if you stop taking Alista suddenly?

A: Official documentation indicates that the decision to discontinue Alista is a clinical one. Stopping this medicine requires professional medical guidance.

Q: How long does Alista stay in the system?

A: Official pharmacological data indicates that the apparent elimination half-life of the active ingredient, Cilostazol, is approximately 11 to 13 hours.

Q: Does Alista have generic versions available?

A: Yes, the active ingredient, Cilostazol, is available in generic form.

Q: What over-the-counter pain relievers can interact with Alista?

A: Official drug information warns that Alista may increase the risk of bleeding when combined with other agents that inhibit platelet aggregation. This group can include certain over-the-counter agents that affect platelet function.

Q: Is Alista a controlled substance?

A: No, the active ingredient in Alista, Cilostazol, is not classified as a federally controlled substance.

Q: What is the risk of an allergic reaction to Alista?

A: Serious adverse reactions including allergic reactions (such as anaphylaxis or angioedema) have been reported during post-marketing use of the drug.

Q: Does Alista come with a Patient Information Leaflet?

A: Yes, regulatory requirements mandate that this medicine typically comes with a Patient Information Leaflet, which is a regulatory requirement to provide detailed information about the medicine's proper use and risks.

Alista (Cilostazol tablets) must be stored and handled according to the requirements stated in official regulatory labeling to maintain stability and ensure safety.

Storage Conditions

The required storage temperature is 25 C (77 F), with excursions permitted to range from 15 C to 30 C (59 F to 86 F), corresponding to Controlled Room Temperature. The medication must be kept in a tight container and stored away from excess heat and moisture. It is mandatory to keep this medicine out of the sight and reach of children and pets.

Disposal Requirements

Official disposal guidelines state that unused or expired tablets should not be thrown away via wastewater or household waste to protect the environment. Patients are instructed to consult a pharmacist or utilize an official drug take-back program for safe disposal.